Iterum Therapeutics PLC (NASDAQ:ITRM) reported its fourth-quarter 2024 financial results, revealing a narrower-than-expected loss. The company posted an actual EPS of -0.12, beating the forecasted EPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback